UK: World Alzheimer's Day

Last Updated: 3 October 2018
Article by Mark Steedman

In the late 1970s, Earth, Wind & Fire released one of their biggest hits – September – with an opening line that has become an internet meme and is widely recognised around the world.

"Do you remember the 21st night of September?"

Fast forward to today, an important date in the calendar for the millions of people suffering from Alzheimer's disease and other forms of dementia. The 21st of September 2018 is World Alzheimer's Day, an important opportunity for raising awareness and highlighting many of the issues that people suffering from dementia face every day. The theme of this year's campaign is 'Unite against dementia' and how, by working together, we can overcome many of the challenges those with dementia face and allow those with dementia to live as well as possible.

Dementia is not a specific disease but a term that describes a group of symptoms associated with a decline in memory, thinking, behaviour and the ability to perform everyday activities. The World Health Organization characterises dementia into three stages, each of which are distinguished by a variety of symptoms (see Figure 1). It affects around 50 million people around the world – mainly older people, although it is not a normal part of ageing, as is believed by many. Nearly 60 per cent of those with dementia live in low and middle-income countries, and due to the world's growing and ageing population, there are nearly 10 million new cases every year. It is one of the major causes of disability and dependency worldwide among older people and has significant physical, psychological, social and economic impacts, not only on people with dementia but also on their carers, families and society.1

Figure 1. Stages and symptoms of dementia, which may or may not be present in all cases

Source: adapted from the World Health Organization, Dementia Key facts, 2017

Alzheimer's disease (AD) is the most common form of dementia and is believed to contribute to approximately 60 to 70 per cent of all dementia cases. Currently, there is no cure for AD, although various medication and management strategies may help to alleviate symptoms on a temporary basis. Little is known about the causes of the disease, but about 70 percent of the risk is believed to be genetic.2 Other risk factors are believed to be hypertension, depression, head injuries and more recent research suggests air pollution may be a factor in some cases. At the cellular level, AD is characterised by two main pathologies:

  • amyloid plaques: the accumulation of protein fragments called beta amyloid that form plaques between neurons in the brain. Beta amyloid is broken down and eliminated in a healthy brain, but in AD the fragments accumulate to form hard, insoluble plaques
  • neurofibrillary tangles: twisted fibres inside neurons that mainly consist of a protein called tau, which forms part of structures called microtubules that transport nutrients and other molecules from one part of a neuron to another. In AD, tau is abnormal and microtubules collapse, affecting molecular transport3

Consequently, many current drug development strategies focus on targeting either beta amyloid or tau, although with very limited results. In 2016, a clinical trial using a tau-based drug found that the drug reduced brain shrinkage by 30-40 per cent and resulted in improvements in memory and thinking tests compared to the control group. However, these promising results were only found in patients not taking any other medications for AD. This represented only a small subset of the trial population, so overall the trial failed to meet its goal, leaving a number of unanswered questions but also plans for further trials to confirm the initial results and determine optimal dosing.4

These potentially promising results follow many years of failures. We explored these failures in more detail in our report The future awakens: Life sciences and health care predictions 2022, in which we noted that between 1998 and 2014, 123 potential medicines for AD were halted in clinical trials, and just four medicines were approved (see Figure 2). In 2017, there were 87 potential drugs in development for AD in the US, including 16 in phase III clinical trials. Many of these potential drugs focus on the aforementioned amyloid plaques and neurofibrillary tangles, although others are aimed at decreasing inflammation in the brain due to AD or target the immune system to fight AD. Prevention of AD is also an important area of interest, and researchers are exploring gene mutations associated with AD.5

Figure 2. The search for a treatment for Alzheimer's Disease

Source: The future awakens: Life sciences and health care predictions 2022, Deloitte LLP, 2017

This historic lack of treatment to either halt or even cure AD, along with the sheer scale and impact of the disease on families, carers and the health and social care system, have contributed to the high cost of dementia in every health economy around the world. In the UK, a 2017 estimate put this cost at £23 billion per year,6 while in 2018 it rose to £26 billion per year. This is more than cancer and heart disease combined, yet research into dementia is often neglected, as only £90 per patient is spent on dementia research each year in the UK.7

However, the lack of new drug treatments and overall small amount of funding for dementia research is not all bad news. Recently there have been some innovative breakthroughs and new strategies around dementia diagnosis, raising hope that a cure could be found one day. In Japan, a new artificial intelligence-based diagnostic tool that utilises a series of questions and an on screen avatar has been developed to detect individuals in the early stages of dementia.8 Similarly, here in the UK, machine learning has been deployed to detect small vessel disease, one of the most common causes of stroke and dementia, which could be utilised to help clinicians administer treatments to patients more quickly in emergency settings and predict a patient's likelihood of developing dementia.9

Applying these types of new technologies could impact dementia diagnosis and treatment in the coming years. Similarly, an increased focus on developing new drugs for dementia could eventually lead to numerous breakthroughs that could limit the extent of the effects of dementia on the global population, so that eventually everyone can remember tonight, the 21st night of September.

In the UK, dementia awareness and understanding has come a long way. However, the stigmatisation and misinformation that surrounds dementia remain a challenge and, as we illustrate above, more research into this devastating disease is still needed. Between 2013 and 2016, we worked closely with the Alzheimer's Society, one of Deloitte's three main charity partners, to improve awareness and understanding of dementia. The Centre for Health Solutions also published a joint report - Dementia today and tomorrow: A new deal for people with dementia and their carers.10 Many Deloitte employees became Dementia Friends, including our Executive team,11 and we continue to support this most important of causes. So today, on World Alzheimer's day, we have dedicated our blog to updating our readers on developments in the fight against dementia and to remind everyone as to why we need to continue to unite and work together to raise awareness and challenge the common stigma that surrounds Alzheimer's Disease and other dementias.

Unite against dementia













The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions